The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study - Finn, R S; Crown, J P; Lang, I; Boer, K; Bondarenko, I M; Kulyk, S O; Ettl, J; Patel, R; Pinter, T; Schmidt, M (Lancet Oncol, 2015)
et al.